China-based nerve and peripheral vascular interventional device developer Zylox-Tonbridge Medical Technology (HKG: 2190) has announced a strategic partnership with Guangdong Hicicare Science Co., Ltd. The collaboration aims to promote and sell Zylox-Tonbridge’s peripheral vascular intervention and neurovascular intervention guide wire products in China. Financial details of the agreement were not disclosed.
Expanding Product Offerings to Meet Clinical Needs
Zylox-Tonbridge’s peripheral vascular intervention business unit plans to launch a series of guide wire products designed to address a range of clinical needs, from imaging diagnosis to the opening and treatment of diseases such as stenosis, moderate to severe calcification, and complete occlusion. This move is in line with the company’s commitment to providing innovative solutions for vascular interventions.
Neurovascular Intervention Unit’s Product Launch
In the neurovascular intervention space, Zylox-Tonbridge has launched the microwire series to cater to the diverse clinical treatment needs of ischemic and hemorrhagic stroke patients. This product line expansion is set to enhance the company’s presence in the neurovascular intervention market.
Growing Market Potential for Nerve and Peripheral Vascular Interventions
The number of nerve intervention surgeries in China is projected to increase significantly, from 159,600 in 2019 to an estimated 1,781,000 by 2030. Similarly, the number of peripheral artery intervention surgeries is expected to see a substantial jump, from 112,200 in 2019 to 600,100 by 2030. These statistics highlight the growing market potential for companies like Zylox-Tonbridge Medical Technology that specialize in nerve and peripheral vascular interventional devices.-Fineline Info & Tech
